BioSpace News Archive

Delve Bio debuts with $35 million in Series A financing led by Perceptive Xontogeny Venture Fund II (PXV Fund II) – and joined by Section 32 and GV.

LODOCO ® (colchicine, 0.5 mg tablet) Reduces Cardiac Event Risk in Adult Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) by an Additional 31 % on Top of Standard of Care. LODOCO Targets Residual Inflammation as an Underlying Cause of ASCVD and Can be Used Alone or in Combination with Cholesterol-Lowering Medications PARSIPPANY, N.J.--( BUSINESS WIRE )-- AGEPHA Pharma USA, LLC , today announced that, following a Priority Review, the U.S. Food and

Aiosyn, a medical software company specializing in AI-powered pathology solutions, released its first AI algorithm in its Mitosis product family: Aiosyn Mitosis Research.

Sientra, Inc. announced the appointment of Alexander W. Casdin to the Company’s Board of Directors, effective June 15, 2023.

Intelligent Bio Solutions Inc. today announced it has received a second progress payment of USD $1.43 million as part of a scientific grant awarded to the Company in 2021 for USD $4.7 million, as announced by the Company on July 8, 2021.

Non-small cell lung cancer is one of the most common and aggressive forms of cancer. Researchers have been exploring effective treatments to improve the survival rates of patients with NSCLC, such as by targeting the immune cells in the tumor microenvironment.

Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Napo Pharmaceuticals, Jaguar’s wholly owned subsidiary, is now a Corporate Partner of the Multinational Association of Supportive Care in Cancer (MASCC).

Curia today announced it has signed a licensing agreement with MilliporeSigma, the North American Life Sciences Business of Merck KGaA, Darmstadt, Germany, that enables Curia and its clients to use the CHOZN® GS-/- cell line for production of therapeutic proteins and antibodies.

Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE.

Merck, known as MSD outside of the United States and Canada, announced topline results from the Phase 3 KEYNOTE-585 trial, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, followed by adjuvant treatment with KEYTRUDA plus chemotherapy, then KEYTRUDA monotherapy in patients with locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.